Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1999-01-07
2000-08-08
Patterson, Jr., Charles L.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
435196, 4352523, 4353201, 536 232, C12N 916, C12N 1555
Patent
active
06100037&
ABSTRACT:
The invention provides human cyclic nucleotide phosphodiesterases (HSPDE10A) and polynucleotides which identify and encode HSPDE10A. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPDE10A.
REFERENCES:
Beavo, J. A., Cyclic Nucleotide Phosphodiesterases: Functional Implications of Multiple Isoforms, Physiological Reviews, 75 (4) :725-48, (Oct. 1995).
McAllister-Lucas, L.M. et al., The Structure of a Bovine Lung cGMP-binding, cGMP-specific Phosphodiesterase Deduced from a cDNA Clone, J. Biol. Chem. 268(30) :22863-22873, (1993).
Turko, I. V. et al., Identification of Key Amino Acids in a Conserved cGMP-binding Site of cGMP-binding Phosphodiesterases, J. Biol. Chem. 271(36) :22240-22244, (1996).
Angel, Rolipram, a specific type IV phosphodiesterase inhibitor is a potent inhibitor of HIV-1 replication, J. B. et al., AIDS 9:1137-44, (1995).
Sommer, The antidepressant roligram suppresses cytokine production and prevents autoimmune enephalomyelitis, N. et al., Nat. Med. 1(3) :244-248, (1995).
Sasaki, H. et al., Suppression of oro-facial movements by roligram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol, Eur. J. Pharmacol 282:71-76, (1995).
Banner, K.H. and Page, Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in treatment of bronchial asthma, C.P., Eur. Respir. J. 8:996-1000, (1995).
Bang et al., Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP, Proc. Natl. Acad. Sci. 91:5330-5334, (1994).
Matousovic, K. et al., Inhibitors of Cyclic Nucleotide Phosphodiesterase Isozymes Type-III and Type-IV Suppress Mitogenesis of Rat Mesangial Cells, J. Clin. Invest. 96:401-410, (1995).
Joulain, C. et al., Influence of polyunsaturated fatty acids on lipid metabolism in human blood mononuclear cells and early biochemical events associated with lymphocyte activation, J. Lipid Mediat. Cell Signal. 11:63-79, (1995).
Deonarain et al., Targeting enzymes for cancer therapy: old enzymes in new roles, Br. J. Cancer 70:786-94, (1994).
Stacey, P., et al., (GI 3355605), GenBank Sequence Database (Accession AJ004865), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894 (1998).
Bandman Olga
Fawcett Lindsay
Lanfear Jeremy
Phillips Stephen C.
Incyte Pharmaceuticals Inc.
Murry Lynn E.
Patterson Jr. Charles L.
LandOfFree
Human cyclic nucleotide PDEs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human cyclic nucleotide PDEs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human cyclic nucleotide PDEs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1148894